Abbvie (ABBV)
NYSE:ABBV
Want to see ABBV full AI Analyst Report?
Top Page
AbbVie
(NYSE:ABBV)
Select Model
Select Model
Rating:60Neutral
Price Target:
$219.00
▲(5.10% Upside)
Action:Reiterated
Date:05/14/26
ABBV scores as balanced: strong cash generation and a raised FY2026 outlook support the thesis, but the debt-heavy balance sheet and sharply lower net margin versus prior years are meaningful risks. Technically, momentum is soft (below key moving averages with negative MACD), and the very high P/E limits valuation support despite the solid dividend.
Positive Factors
Cash-generation strength
AbbVie’s large, growing free cash flow (TTM ~ $20.9B, +11.6%) is a durable structural strength: it funds R&D, manufacturing buildouts, dividends and BD activity without reliance on near-term equity or asset sales. Strong cash conversion supports strategic flexibility over coming quarters.
Negative Factors
Heavy leverage
Very high absolute and relative debt levels materially constrain strategic flexibility: interest and refinancing risk rise, credit-sensitive spends become harder to scale, and management’s capital allocation (M&A, buybacks) faces limits if earnings dip over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash-generation strength
AbbVie’s large, growing free cash flow (TTM ~ $20.9B, +11.6%) is a durable structural strength: it funds R&D, manufacturing buildouts, dividends and BD activity without reliance on near-term equity or asset sales. Strong cash conversion supports strategic flexibility over coming quarters.
Read all positive factors
AbbVie Key Performance Indicators (KPIs)
Any
Revenue by Geography
Illustrates where AbbVie generates cash around the world and which regions drive growth or volatility. Geographic trends can flag where pricing pressure, local competition, or launch success will meaningfully affect total revenue and help assess the company’s ability to offset declines in one market with gains in another.
Illustrates where AbbVie generates cash around the world and which regions drive growth or volatility. Geographic trends can flag where pricing pressure, local competition, or launch success will meaningfully affect total revenue and help assess the company’s ability to offset declines in one market with gains in another.
Data provided by:
The Fly
The FlyAbbVie (ABBV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$375.09B
Dividend Yield2.87%
Average Volume (3M)6.50M
Price to Earnings (P/E)138.0
Beta (1Y)0.22
Revenue Growth9.50%
EPS Growth-13.63%
CountryUS
Employees55,000
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)2.04
Shares Outstanding1,766,792,800
10 Day Avg. Volume5,622,516
30 Day Avg. Volume6,501,409
Financial Highlights & Ratios
PEG Ratio-77.01
Price to Book (P/B)-124.40
Price to Sales (P/S)6.65
P/FCF Ratio22.83
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue6.98
Enterprise Value/Gross Profit9.50
Enterprise Value/Ebitda24.42
Forecast
1Y Price Target
$253.89Price Target Upside21.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
EPS Forecast (FY)14.23
Revenue Forecast (FY)$67.28B
AbbVie Business Overview & Revenue Model
Company Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaqu...
How the Company Makes Money
AbbVie makes money primarily by selling branded prescription drugs and medical aesthetics products worldwide. Its revenue model is largely product-sales driven: (1) Immunology: AbbVie generates significant sales from immunology therapies, notably ...
AbbVie Earnings Call Summary
Earnings Call Date:Apr 29, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 24, 2026
Earnings Call Sentiment Positive
The call conveyed strong commercial momentum and financial performance with multiple product growth drivers (Skyrizi, Rinvoq, neuroscience portfolio) and a raised full-year outlook. Substantial pipeline progress (regulatory submissions, combination Crohn's data, obesity signal) and major manufacturing investments reinforce long-term growth positioning. Offsets include expected HUMIRA biosimilar erosion, pressure in some oncology and aesthetic segments, selected clinical setbacks/non-differentiation and near-term acquired IPR&D expense impacts. On balance, highlights — including robust sales beats, double-digit growth for key franchises, guidance raise, and encouraging pipeline readouts — outweigh the lowlights.Positive Updates
Quarterly Financial Beat and Guidance Raise
Adjusted EPS of $2.65, $0.07 above guidance midpoint; total net revenues of $15.0 billion, beating expectations by ~$300 million and representing 12.4% sales growth. Company raised full-year adjusted EPS guidance by $0.12 to $14.08–$14.28 and increased full-year revenue outlook to approximately $67.3 billion (+$300 million).
Negative Updates
HUMIRA Sales Decline from Biosimilars
HUMIRA global sales $688 million, down 40.3% (operational), reflecting expected biosimilar erosion and contributing to overall portfolio transitions.
Read all updates
Q1-2026 Updates
Positive
Negative
Quarterly Financial Beat and Guidance Raise
Adjusted EPS of $2.65, $0.07 above guidance midpoint; total net revenues of $15.0 billion, beating expectations by ~$300 million and representing 12.4% sales growth. Company raised full-year adjusted EPS guidance by $0.12 to $14.08–$14.28 and increased full-year revenue outlook to approximately $67.3 billion (+$300 million).
Read all positive updates
Company Guidance
AbbVie raised full‑year 2026 adjusted EPS guidance by $0.12 to $14.08–$14.28 (guidance excludes any estimate for acquired IPR&D beyond Q1) after a strong Q1 beat (adjusted EPS $2.65, $0.07 above midpoint; total net revenues $15.0B, +12.4% with a 2.1% FX tailwind). Management now expects full‑year net revenues of ~$67.3B (up $300M) and Q2 revenues of ~$16.7B (estimated 0.6% FX benefit); product assumptions include Skyrizi $21.6B (+$100M), Rinvoq $10.2B (+$100M) and total neuroscience $12.6B (+$100M). They forecast adjusted gross margin above 84% of sales (Q1 was 83.6%), adjusted R&D ≈$9.7B, adjusted SG&A ≈$14.2B, an adjusted operating margin of ~47.5% for the year (Q2 guide ≈50%), adjusted net interest expense ≈$2.7B (down $100M) and referenced a Q1 adjusted tax rate of 15.4%.AbbVie Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
38
Negative
Cash Flow
78
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 62.82B | 61.16B | 56.33B | 54.32B | 58.05B | 56.20B |
| Gross Profit | 46.15B | 42.96B | 39.43B | 33.90B | 40.64B | 38.75B |
| EBITDA | 17.96B | 17.63B | 14.91B | 17.17B | 24.17B | 23.93B |
| Net Income | 3.64B | 4.23B | 4.28B | 4.86B | 11.84B | 11.54B |
Balance Sheet | ||||||
| Total Assets | 136.46B | 133.96B | 135.16B | 134.71B | 138.81B | 146.53B |
| Cash, Cash Equivalents and Short-Term Investments | 9.39B | 5.26B | 5.55B | 12.82B | 9.23B | 9.83B |
| Total Debt | 72.86B | 69.07B | 67.84B | 60.12B | 64.19B | 77.58B |
| Total Liabilities | 108.96B | 137.19B | 131.80B | 124.31B | 121.52B | 131.09B |
| Stockholders Equity | 27.50B | -3.27B | 3.33B | 10.36B | 17.25B | 15.41B |
Cash Flow | ||||||
| Free Cash Flow | 20.86B | 17.82B | 17.83B | 22.06B | 24.25B | 21.99B |
| Operating Cash Flow | 21.22B | 19.03B | 18.81B | 22.84B | 24.94B | 22.78B |
| Investing Cash Flow | -6.48B | -6.64B | -20.82B | -2.01B | -623.00M | -2.34B |
| Financing Cash Flow | -10.55B | -12.72B | -5.21B | -17.22B | -24.80B | -19.04B |
AbbVie Technical Analysis
Positive
208.38
Price Trends
207.93
Positive
215.27
Negative
216.09
Negative
Market Momentum
1.03
Negative
57.43
Neutral
75.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABBV, the sentiment is Positive. The current price of 208.38 is above the 20-day moving average (MA) of 205.79, above the 50-day MA of 207.93, and below the 200-day MA of 216.09, indicating a neutral trend. The MACD of 1.03 indicates Negative momentum. The RSI at 57.43 is Neutral, neither overbought nor oversold. The STOCH value of 75.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ABBV.
AbbVie Risk Analysis
AbbVie disclosed 31 risk factors in its most recent earnings report. AbbVie reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AbbVie Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $552.02B | 28.32 | 26.26% | 2.50% | 7.87% | -3.56% | |
71 Outperform | £216.34B | 24.41 | 22.41% | 1.53% | 4.64% | 26.75% | |
69 Neutral | $107.33B | 15.55 | 14.41% | 4.58% | 11.19% | -0.23% | |
65 Neutral | $279.09B | -17.53 | 17.93% | 3.12% | 2.70% | -48.28% | |
63 Neutral | $146.99B | 14.70 | 8.37% | 6.65% | 1.36% | -5.39% | |
60 Neutral | $375.09B | 137.98 | 68.01% | 2.87% | 9.50% | -13.63% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
ABBV
AbbVie
212.30
36.24
20.58%
JNJ
Johnson & Johnson
229.32
80.29
53.88%
MRK
Merck & Company
113.00
38.72
52.13%
PFE
Pfizer
25.79
4.25
19.76%
SNY
Sanofi
44.67
-6.20
-12.19%
GB:AZN
AstraZeneca
13,950.00
3,637.73
35.28%
AbbVie Corporate Events
Executive/Board ChangesShareholder Meetings
AbbVie Shareholders Back Directors, Maintain Governance Structure
Neutral
May 12, 2026
At AbbVie’s 2026 Annual Meeting of Stockholders held on May 8, 2026, shareholders elected four Class II directors—Jennifer L. Davis, Melody B. Meyer, Robert A. Michael and Frederick H. Waddell—to terms expiring in 2029 and ratifi...
Business Operations and StrategyPrivate Placements and Financing
AbbVie Completes $8 Billion Senior Notes Financing Offering
Positive
Mar 4, 2026
On March 4, 2026, AbbVie completed an underwritten public notes offering totaling $8 billion, spanning a mix of senior floating rate notes and unsecured fixed-rate senior notes with maturities ranging from 2028 to 2066. The securities, issued unde...
Business Operations and StrategyPrivate Placements and Financing
AbbVie Announces $7.5 Billion Senior Notes Offering
Neutral
Feb 26, 2026
On February 24, 2026, AbbVie entered into an underwriting agreement with a syndicate of major banks to issue a total of $7.5 billion in senior notes across multiple tranches maturing between 2028 and 2066, including floating rate and fixed-rate in...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.